

Discovery Services

Certificate of Analysis

PAK5, active

(Recombinant enzyme expressed in Sf21 insect cells) Item # 14-699, 14-699-K, 14-699M Parent Lot # D8CN021U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: *N*-terminal 6Histagged, recombinant, human PAK5, amino acids 425–end, expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 95.8% by SDS-PAGE and Coomassie blue staining. MW = 37.4kDa.

Specific Activity (Parent lot# D8CN021U): 2565U/mg, where one unit of PAK5 activity is defined as 1nmol phosphate incorporated into PAKtide per minute at 30°C with a final ATP concentration of 100µM. **Formulation: 2.067mg/ml** of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

FOR IN VITRO RESEARCH USE ONLY NOT FOR USE IN HUMANS OR ANIMALS

Quality Control Testing

<u>Kinase Assay</u>: 1.81–5.00ng of this lot of enzyme phosphorylated 200µM PAKtide in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.





Eurofins Pharma C Discovery Services UK C Limited C

Gemini Crescent Dundee Technology Park DUNDEE DD2 1SW United Kingdom



Discovery Services

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 5 x Reaction Buffer: 40mM MOPS-NaOH pH7.0, 1mM EDTA.
- PAKtide (RRRLSFAEPG): Use at a final assay concentration of 200µM. Prepare 2mM stock and add 2.5µl of stock per assay point.
- 3. PAK5, active: Dilute with 20mM MOPS-NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 1.81–5.00ng per assay point.
- [γ-³³P]ATP: 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

- 1. Add 5µl of 5 x reaction buffer per assay to wells.
- 2. Add 2.5µl of **PAKtide**.
- 3. Add 2.5µl (1.81–5.00ng) PAK5, active.
- 4. Add 5μ I of dH₂O.
- 5. Add 10µl of diluted [γ -³³P]ATP mixture.
- 6. Incubate for 10 minutes at 30°C.
- 7. Stop the reaction by adding 5µl of 3% phosphoric acid.
- 8. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
- 9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
- 10. Wash the filtermat once for 2 minutes with methanol.
- 11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
- 12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.



Certificate of Analysis

PAK5 Sequence Information

Protein	Human PAK5
Tags	N-Terminal 6His
Native sequence	GenBank NM_020341
Accession number	S31 of recombinant sequence is equivalent to S425 of human PAK5

Recombinant PAK5 amino acid sequence:

1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF SRVSHEQFRA ALQLVVSPGD PREYLANFIK 61 IGEGSTGIVC IATEKHTGKQ VAVKKMDLRK QQRRELLFNE VVIMRDYHHD NVVDMYSSYL 121 VGDELWVVME FLEGGALTDI VTHTRMNEEQ IATVCLSVLR ALSYLHNQGV IHRDIKSDSI 181 LLTSDGRIKL SDFGFCAQVS KEVPKRKSLV GTPYWMAPEV ISRLPYGTEV DIWSLGIMVI 241 EMIDGEPPYF NEPPLQAMRR IRDSLPPRVK DLHKVSSVLR GFLDLMLVRE PSQRATAQEL 301 LGHPFLKLAG PPSCIVPLMR QYRHH

Recombinant PAK5 nucleotide sequence:

1	atgtcgtact	accatcacca	tcaccatcac	gattacgata	tcccaacgac	cgaaaacctg
61	tattttcagg	gcgccatgga	tccggaattc	tccagggtgt	cccatgaaca	gtttcgggcg
121	gccctgcagc	tggtggtcag	cccaggagac	cccagggaat	acttggccaa	ctttatcaaa
181	atcggggaag	gctcaaccgg	catcgtatgc	atcgccaccg	agaaacacac	agggaaacaa
241	gttgcagtga	agaaaatgga	cctccggaag	caacagagac	gagaactgct	tttcaatgag
301	gtcgtgatca	tgcgggatta	ccaccatgac	aatgtggttg	acatgtacag	cagctacctt
361	gtcggcgatg	agctctgggt	ggtcatggag	tttctagaag	gtggtgcctt	gacagacatt
421	gtgactcaca	ccagaatgaa	tgaagaacag	atagctactg	tctgcctgtc	agttctgaga
481	gctctctcct	accttcataa	ccaaggagtg	attcacaggg	acataaaaag	tgactccatc
541	ctcctgacaa	gcgatggccg	gataaagttg	tctgattttg	gtttctgtgc	tcaagtttcc
601	aaagaggtgc	cgaagaggaa	atcattggtt	ggcactccct	actggatggc	ccctgaggtg
661	atttctaggc	taccttatgg	gacagaggtg	gacatctggt	ccctcgggat	catggtgata
721	gaaatgattg	atggcgagcc	cccctacttc	aatgagcctc	ccctccaggc	gatgcggagg
781	atccgggaca	gtttacctcc	aagagtgaag	gacctacaca	aggtttcttc	agtgctccgg
841	ggattcctag	acttgatgtt	ggtgagggag	ccctctcaga	gagcaacagc	ccaggaactc
901	ctcggacatc	cattcttaaa	actagcaggt	ccaccgtctt	gcattgtccc	cctcatgaga
961	caatacaqqc	atcactga				

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.